Disease · MONDO_0005040

germ cell tumor

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. germ cell tumor. Diseases, record MONDO_0005040. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005040

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: germ cell tumor; Open Targets
Open Targets ID: MONDO_0005040; Open Targets
Other names: germ cell neoplasm, neoplasm of germ cell, neoplasm of the germ cell, tumor of germ cell, tumor of the germ cell, tumour of germ cell, tumour of the germ cell; Open Targets
Disease Ontology: DOID:2994; Disease Ontology
NCI Thesaurus: C3708; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 68 drugs, from PMDA; Open Targets

Drugs68

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IFOSFAMIDE	CHEMBL1024	Small molecule	Approval	PMDA	22	21	21	Drugs and targets
BLEOMYCIN	CHEMBL6067492		Approval	PMDA	6	5	5	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	25	25	25	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	25	25	25	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	24	24	24	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	19	19	19	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	13	13	13	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
PEGFILGRASTIM	CHEMBL1201568	Protein	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
BLEOMYCIN SULFATE	CHEMBL6067493		Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 68

See all 68 drugs

Targets76

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBA1A	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/347733	Drugs and targets

1 to 10 of 76

See all 76 targets

Trials82

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02454972	Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors	Phase 2	345	2021-11-22	Advanced Solid Tumors	LURBINECTEDIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01037790	Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	Phase 2	304	2021-03-11	Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Benign Teratoma, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Familial Testicular Germ Cell Tumor, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Male Breast Cancer, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Monodermal and Highly Specialized Teratoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Melanoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Rectal Cancer, Stage III Extragonadal Non-seminomatous Germ Cell Tumor, Stage III Extragonadal Seminoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Extragonadal Non-seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Melanoma, Stage IV Ovarian Germ Cell Tumor, Stage IV Rectal Cancer, Testicular Immature Teratoma, Testicular Mature Teratoma	PALBOCICLIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00002558	Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors	Phase 1/2	108	2016-05-23	Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor	CARBOPLATIN, ETOPOSIDE, FILGRASTIM, IFOSFAMIDE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00936936	High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors	Phase 2	64	2024-08-26	Testicular Cancer	BEVACIZUMAB, CARBOPLATIN, DOCETAXEL, ETOPOSIDE, GEMCITABINE, IFOSFAMIDE, MELPHALAN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00470366	Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors	Phase 2	60	2017-10-24	Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor	CISPLATIN, IFOSFAMIDE, PACLITAXEL, PEGFILGRASTIM	Its record names the disease	ClinicalTrials.gov
NCT00957905	Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors	Phase 2	36	2017-03-10	Recurrent Extragonadal Seminoma, Recurrent Malignant Extragonadal Germ Cell Tumor, Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage III Testicular Cancer, Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Ovarian Germ Cell Tumor	ALVOCIDIB, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00393861	Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients	Phase 2	29	2015-01-29	Neoplasms, Germ Cell and Embryonal	BEVACIZUMAB, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT01055067	ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors	Phase 2	27	2020-09-09	Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas)	TIVANTINIB	Its record names the disease	ClinicalTrials.gov
NCT00423852	Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin	Phase 1/2	26	2016-05-18	Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor	CARBOPLATIN, IFOSFAMIDE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00085098	Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor	Phase 3	24	2013-11-06	Brain Tumor, Central Nervous System Tumor	CARBOPLATIN, CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, FILGRASTIM	Its record names the disease	ClinicalTrials.gov

1 to 10 of 82

See all 82 trials

Comparisons in its trials19

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Group A: <= 6 Cycles of Cisplatin vs Group: B > 6 Cycles of Cisplatin: serious adverse events	7 of 92	2 of 16	108	NCT00002558	Trial comparisons
Cohort 1: HD GeM-DMC+ ICE + Bevacizumab for Refractory GCT vs Cohort 2: HD GeM-DMC+ ICE for Refractory GCT: Number of Participants With 2-year Event-Free Survival (EFS)	28 of 41	11 of 23	64	NCT00936936	Trial comparisons
Cohort 1: HD GeM-DMC+ ICE + Bevacizumab for Refractory GCT vs Cohort 2: HD GeM-DMC+ ICE for Refractory GCT: deaths from any cause	22 of 41	12 of 23	64	NCT00936936	Trial comparisons
Cohort 1: HD GeM-DMC+ ICE + Bevacizumab for Refractory GCT vs Cohort 2: HD GeM-DMC+ ICE for Refractory GCT: Overall Survival	25 of 41	9 of 23	64	NCT00936936	Trial comparisons
Cohort 1: HD GeM-DMC+ ICE + Bevacizumab for Refractory GCT vs Cohort 2: HD GeM-DMC+ ICE for Refractory GCT: serious adverse events	7 of 41	2 of 23	64	NCT00936936	Trial comparisons
Stage 1: ARQ 197 360 mg BID vs Total: deaths from any cause	0 of 21	0 of 27	48	NCT01055067	Trial comparisons
Stage 1: ARQ 197 360 mg BID vs Total: serious adverse events	6 of 21	9 of 27	48	NCT01055067	Trial comparisons
Part A (Alvocidib and Oxaliplatin) vs Part B (Alvocidib and FOLFOX): serious adverse events	4 of 7	7 of 29	36	NCT00957905	Trial comparisons
2 Transplants vs 1 Transplant: Numbers of Patients Unable to Mobilize Peripheral Blood Stem Cells	0 of 14	0 of 9	23	NCT00432094	Trial comparisons
2 Transplants vs 1 Transplant: Engraftment of Platelets	13 of 14	8 of 9	23	NCT00432094	Trial comparisons

1 to 10 of 19

See all 19 comparisons in its trials

Papers from its trials37

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33675184	RESULT	1	PubMed
31595663	RESULT	1	PubMed
25001888	RESULT	1	PubMed
20194867	RESULT	1	PubMed
19547919	RESULT	1	PubMed
18623206	RESULT	1	PubMed
17290059	RESULT	1	PubMed
17235042	RESULT	1	PubMed
17194908	RESULT	1	PubMed
15999102	RESULT	1	PubMed

1 to 10 of 37

See all 37 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005040

GET https://conductscience.org/api/diseases/v1/MONDO_0005040/drugs?page=2

API reference For AI assistants